(Q43250046)

English

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

scientific article published on 2 November 2009

Statements

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. (English)
Matthew T Seymour
Philip Chambers
Faye Elliott
Catherine L Daly
Angela M Meade
Graham Taylor
2 November 2009
5931-5937

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit